- Home
- SKIN vs ANNX Comparison
SKIN vs ANNX Comparison
Compare SKIN & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- ANNX
- Stock Information
- Founded
- SKIN 1997
- ANNX 2011
- Country
- SKIN United States
- ANNX United States
- Employees
- SKIN N/A
- ANNX N/A
- Industry
- SKIN Package Goods/Cosmetics
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- SKIN Consumer Discretionary
- ANNX Health Care
- Exchange
- SKIN Nasdaq
- ANNX Nasdaq
- Market Cap
- SKIN 280.3M
- ANNX 257.8M
- IPO Year
- SKIN N/A
- ANNX 2020
- Fundamental
- Price
- SKIN $2.17
- ANNX $2.42
- Analyst Decision
- SKIN Sell
- ANNX Strong Buy
- Analyst Count
- SKIN 2
- ANNX 4
- Target Price
- SKIN $1.13
- ANNX $12.50
- AVG Volume (30 Days)
- SKIN 1.4M
- ANNX 1.1M
- Earning Date
- SKIN 08-07-2025
- ANNX 08-19-2025
- Dividend Yield
- SKIN N/A
- ANNX N/A
- EPS Growth
- SKIN N/A
- ANNX N/A
- EPS
- SKIN N/A
- ANNX N/A
- Revenue
- SKIN $310,064,000.00
- ANNX N/A
- Revenue This Year
- SKIN N/A
- ANNX N/A
- Revenue Next Year
- SKIN $5.73
- ANNX N/A
- P/E Ratio
- SKIN N/A
- ANNX N/A
- Revenue Growth
- SKIN N/A
- ANNX N/A
- 52 Week Low
- SKIN $0.78
- ANNX $1.29
- 52 Week High
- SKIN $2.56
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- SKIN 60.54
- ANNX 53.11
- Support Level
- SKIN $1.53
- ANNX $2.31
- Resistance Level
- SKIN $2.56
- ANNX $2.71
- Average True Range (ATR)
- SKIN 0.18
- ANNX 0.15
- MACD
- SKIN 0.07
- ANNX 0.01
- Stochastic Oscillator
- SKIN 64.55
- ANNX 53.33
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.